On Monday Pfizer Inc (PFE.N) said that it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech . Conducted in the United States, the early-stage vaccine